drugset / Trial / NCT04538066
Bryostatin Treatment of Moderately Severe Alzheimer's Disease
Phase 2
Completed
122 enrolled
Neurotrope Bioscience, Inc.
National Institute on Aging (NIA) · collabNational Institutes of Health (NIH) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To evaluate the safety, tolerability, and long-term efficacy of bryostatin 1 (hereafter referred to as bryostatin) for the treatment of moderately severe Alzheimer's disease (AD).
Timeline
- Start
- 2020-08-30
- Primary completion
- 2022-11-16
- Completion
- 2022-11-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | bryostatin 1 | Small molecule | 20 ug | Intravenous |